Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Chapter 21/<strong>Androgens</strong> <strong>and</strong> Male Contraception 415<br />
are, at present, impractical for widespread use. T comb<strong>in</strong>ations with progest<strong>in</strong>s appear<br />
promis<strong>in</strong>g. Ongo<strong>in</strong>g trials with T plus LNG, DSG, CPA, or NETE may offer a usable<br />
option for men, but difficulties <strong>in</strong> T delivery cont<strong>in</strong>ue to h<strong>in</strong>der commercial use. Newer<br />
<strong>and</strong>rogens such as <strong>in</strong>jectable TU <strong>and</strong> MENT may help improve T delivery, avoid<br />
undesirable effects on the prostate, <strong>and</strong> aid <strong>in</strong> the development of a marketable contraceptive<br />
regimen.<br />
REFERENCES<br />
1. Mart<strong>in</strong> CW, Anderson RA, Cheng L, et al. Potential impact of hormonal meal contraception: crosscultural<br />
implications for development of novel male preparations. Hum Reprod 2000;15:637–645.<br />
2. Glasier AF, Anakwe R, Ever<strong>in</strong>gton D, et al. Would women trust their partners to use a male pill? Hum<br />
Reprod 2000;15:646–649.<br />
3. Amory JK, Bremner WJ. The use of testosterone as a male contraceptive. Balliere’s Cl<strong>in</strong> Endocr<strong>in</strong>ol<br />
Metab 1998;12:471–484.<br />
4. World <strong>Health</strong> Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive<br />
efficacy of testosterone-<strong>in</strong>duced azoospermia <strong>and</strong> oligozoospermia <strong>in</strong> normal men. Fertil Steril<br />
1996;65:821–829.<br />
5. H<strong>and</strong>elsman DJ, Farley TM, Peregoudov A,Waites GM. Factors <strong>in</strong> nonuniform <strong>in</strong>duction of azoospermia<br />
by testosterone enanthate <strong>in</strong> normal men. Fertil Steril 1995;63:125–133.<br />
6. Bagatell CJ, Bremner WJ. <strong>Androgens</strong> <strong>in</strong> men-uses <strong>and</strong> abuses. N Engl J Med 1996;334:707–714<br />
7. World <strong>Health</strong> Organization. Contraceptive efficacy of testosterone-<strong>in</strong>duced azoospermia <strong>in</strong> normal<br />
men. Lancet 1990;336:995–999.<br />
8. Bagatell CJ, Heiman JR, Matsumoto AM, et al. Metabolic <strong>and</strong> behavioral effects of high-dose, exogenous<br />
testosterone <strong>in</strong> healthy men. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1994;79:561–567.<br />
9. Meriggiola MC, Marcov<strong>in</strong>a S, Paulsen CA, Bremner WJ. Testosterone enanthate at the dose 200 mg/<br />
week decreases HDL-cholesterol levels <strong>in</strong> healthy men. Int J Androl 1995;18:237–242.<br />
10. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) <strong>in</strong> hypogonadal men: pharmacok<strong>in</strong>etics<br />
<strong>and</strong> pharmacodynamics of the new long-act<strong>in</strong>g <strong>and</strong>rogen ester. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab<br />
1992;75:1204–1210.<br />
11. Sharma RS, Rajalakshmi M, Pal PC, et al. Evaluation of efficacy, safety, <strong>and</strong> reversibility of comb<strong>in</strong>ation<br />
regimen of cyproterone acetate <strong>and</strong> testosterone buciclate <strong>in</strong> bonnet monkeys. Contraception<br />
2000;62:195–201.<br />
12. Coert A, Geelen J, de Visser J, V<strong>and</strong>erVies J. The pharmacology <strong>and</strong> metabolism of testosterone<br />
undecanoate (TU), an new orally active <strong>and</strong>rogen. Acta Endocr<strong>in</strong>ol (Copenh) 1975;79:789–800.<br />
13. Zhang GY, Gu YQ, Wang XH, et al. A pharmacok<strong>in</strong>etic study of <strong>in</strong>jectable testosterone undecanoate<br />
<strong>in</strong> hypogonadal men. J Androl 1998;19:761–768.<br />
14. Behre AM, Abshagen K, Oettel M, et al. Intramuscular <strong>in</strong>jection of testosterone undecanoate for the<br />
treatment of male hypogonadism: phase I studies. Eur J Endrocr<strong>in</strong>ol 1999;140:414–419.<br />
15. Zhang GY, Gu YQ, Wang XH, et al. Injectable testosterone undecanoate for contraception <strong>in</strong> Ch<strong>in</strong>ese<br />
men. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 1999;84:3642–3647<br />
16. Kamischke A, Ploger D, Venherm S, et al. Intramuscular testosterone undecanoate with or without oral<br />
levonorgestrel: a r<strong>and</strong>omized placebo-controlled feasibility study for male contraception. Cl<strong>in</strong><br />
Endocr<strong>in</strong>ol 2000;53:43–52.<br />
17. Kamischke A, Venherm S, Ploger D, et al. Intramuscular testosterone undecanoate <strong>and</strong> norethisterone<br />
enanthate <strong>in</strong> a cl<strong>in</strong>ical trial for male contraception. J Cl<strong>in</strong> Endocr<strong>in</strong>ol Metab 2001;86:303–309.<br />
18. Schurmeyer T, Knuth UA, Belkien L, Nieschlag E. Reversible azoospermia <strong>in</strong>duced by the anabolic<br />
steroid 19-nortestosterone. Lancet 1984;1:417–420.<br />
19. World <strong>Health</strong> Organization. Comparison of two <strong>and</strong>rogens plus depot-medroxyprogesterone acetate<br />
for suppression to azoospermia <strong>in</strong> Indonesian men. Fertil Steril 1993;60:1062–1068.<br />
20. Behre HM, Kliesch S, Lemcke B, et al. Suppression of spermatogenesis to azoospermia by comb<strong>in</strong>ed<br />
adm<strong>in</strong>istration of GnRH antagonist <strong>and</strong> 19-nortestosterone cannot be ma<strong>in</strong>ta<strong>in</strong>ed by this nonaromatizable<br />
<strong>and</strong>rogen alone. Hum Reprod 2001;16:2570–2577.<br />
21. Sundaram K, Kumar N, Bard<strong>in</strong> CW. 7-Alpha-methyl-19-nortestosterone: an ideal <strong>and</strong>rogen for replacement<br />
therapy. Recent Prog Horm Res 1994;49:373–376.